Kliničke studije za Limfom u državi Colorado
16 studija za Limfom traži sudionike na lokacijama u državi Colorado.
Gradovi u državi Colorado
Službeni tekst studije (engleski)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- University Of Colorado, Aurora
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital Colorado - Anschutz Medical Campus, Aurora
U tijeku regrutacijaFaza 1/2
Do 25 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT04094610A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Colorado Blood Institute, Denver
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07221500Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- University of Colorado, Aurora
- Colorado Blood Cancer Institute (Sarah Cannon), Denver
U tijeku regrutacijaFaza 1
Od 18 do 100 godina · Oba spola · Ažurirano 15. ruj 2026. · NCT05798897CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital Colorado, Aurora
U tijeku regrutacijaFaza 1/2
12 Months – 21 Years · Oba spola · Ažurirano 11. ruj 2026. · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Denver
U tijeku regrutacijaFaza 3
Od 18 do 18 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07509151Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0019), Aurora
U tijeku regrutacijaFaza 1/2
6 Months – 17 Years · Oba spola · Ažurirano 6. srp 2026. · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022Survivors Uniting for Remote Guided Exercise
- Human Performance Clinical Research Lab, Fort Collins
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 31. ožu 2026. · NCT07290309A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Colorado Anschutz Medical Campus, Aurora
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2025. · NCT04234048Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.